President Joe Biden signed an executive order to help people travel between states for an abortion; Eli Lilly was ordered to pay $61 million after allegedly underpaying the Medicaid drug rebate program; CVS plans to acquire or take a stake in a primary care industry by the end of 2022.
President Joe Biden signed an executive order yesterday laying the foundation for Medicaid to assist people in travelling between states to access an abortion, the Associated Press reported. Currently, it is illegal to use federal funding toward abortions unless the pregnant person’s life is at risk or the pregnancy resulted from rape or incest. To get around this, HHS would invite states where abortion is legal to apply to use Medicaid funds to “provide reproductive healthcare to women who live in states where abortion is banned,” according to the White House. Details of the order are still being finalized.
A federal court jury ordered Eli Lilly to pay $61 million for skimping on payments to the Medicaid drug rebate program, STAT News reported. This news follows nearly a decade of legal battles in which Lilly was accused of failing to pay rebates in full between 2005 and 2016 and making false statements to CMS about how much the company charged distributors for its drugs. According to the jury, Lilly intentionally underpaid rebates to the program, which resulted in financial losses for the program as a whole and Medicaid agencies in 26 states.
CVS announced its plans to either acquire or take a stake in a primary care company by the end of 2022, CNBC reported. CVS currently has touchpoints across the health care industry, including Aetna, Caremark, and its own MinuteClinic urgent care locations. According to Karen Lynch, CEO of CVS, the company is looking to partner with a health care provider with strong management and tech experience that has potential to grow quickly, as the company’s competition with Amazon and Walgreens intensifies.
US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment
November 27th 2024While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.
Read More
Facility Type Influences Antifibrotic Treatment Rates in Patients With IPF
November 27th 2024A study in Japan found that antifibrotic treatment rates for patients with idiopathic pulmonary fibrosis (IPF) varied by medical facility, with higher treatment rates observed in referral hospitals than in general hospitals or clinics.
Read More
Expert Insights on How Utilization Management Drives Physician Burnout
November 26th 2024On this episode of Managed Care Cast, we speak with the author of a study published in the November 2024 issue of The American Journal of Managed Care® to explore the link between utilization management and physician burnout.
Listen